Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
International Journal of Clinical Oncology
Erschienen in: International Journal of Clinical Oncology 2/2015

01.04.2015 | Introduction to Review Articles

Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor

verfasst von: Hirotaka Iwase

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Excerpt

Metastatic breast cancer (MBC) is not a curable disease except for local recurrence or oligo-metastasis in the non-visceral organs. In fact, the 10-year survival rate after chemotherapy is approximately 5 %, and, for patients who survive, the complete response rate beyond 20 years is only 2–3 % [1, 2]. Consequently, the purpose of treatment is the prolongation of survival and the improvement of quality of life (QOL). By means of advances in treatment with the advent of a large number of new drugs, survival after recurrence has been gradually improved since the 1990s [3, 4]. …
Literatur
1.
Greenberg PA, Hortobagyi GN, Smith TL et al (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer (translated from Eng). J Clin Oncol 14(8):2197–2205 (in Eng)PubMed
2.
Rahman ZU, Frye DK, Smith TL et al (1999) Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference (translated from Eng). Cancer 85(1):104–111 (in Eng)CrossRefPubMed
3.
Gennari A, Conte P, Rosso R et al (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies (translated from Eng). Cancer 104(8):1742–1750 (in Eng)CrossRefPubMed
4.
Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? (translated from Eng). Cancer 100(1):44–52 (in Eng)CrossRefPubMed
5.
Fossati R, Confalonieri C, Torri V et al (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women (translated from Eng). J Clin Oncol 16(10):3439–3460 (in Eng)PubMed
6.
Gralow JR (2005) Optimizing the treatment of metastatic breast cancer (translated from Eng). Breast Cancer Res Treat 89(Suppl 1):S9–S15 (in Eng)CrossRefPubMed
7.
Tot T, Tabar L (2011) The role of radiological–pathological correlation in diagnosing early breast cancer: the pathologist’s perspective (translated from Eng). Virchows Arch 458(2):125–131 (in Eng)CrossRefPubMed
8.
Lianidou ES, Mavroudis D, Georgoulias V (2013) Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer (translated from Eng). Br J Cancer 108(12):2426–2432 (in Eng)CrossRefPubMedCentralPubMed
9.
Rothe F, Laes JF, Lambrechts D et al (2014) Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer (translated from Eng). Ann Oncol 25(10):1959–1965 (in Eng)CrossRefPubMed
10.
Yamamoto N, Watanabe T, Katsumata N et al (1998) Construction and validation of a practical prognostic index for patients with metastatic breast cancer (translated from Eng). J Clin Oncol 16(7):2401–2408 (in Eng)PubMed
11.
Iwase H (2008) Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer (translated from Eng). Breast Cancer 15(4):278–290 (in Eng)CrossRefPubMed
12.
Osborne CK (1998) Tamoxifen in the treatment of breast cancer (translated from Eng). N Engl J Med 339(22):1609–1618 (in Eng)CrossRefPubMed
13.
Howell A, Robertson JF, Abram P et al (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial (translated from Eng). J Clin Oncol 22(9):1605–1613 (in Eng)CrossRefPubMed
14.
Di Leo A, Jerusalem G, Petruzelka L et al (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer (translated from Eng). J Clin Oncol 28(30):4594–4600 (in Eng)CrossRefPubMed
15.
Byrne MJ, Gebski V, Forbes J et al (1997) Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian–New Zealand Breast Cancer Trials Group (translated from Eng). J Clin Oncol 15(9):3141–3148 (in Eng)PubMed
16.
Haddow A, Watkinson JM, Paterson E et al (1944) Influence of synthetic oestrogens on advanced malignant disease (translated from Eng). Br Med J 2(4368):393–398 (in Eng)CrossRefPubMedCentralPubMed
17.
Ellis MJ, Gao F, Dehdashti F et al (2009) Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study (translated from Eng). JAMA 302(7):774–780 (in Eng)CrossRefPubMedCentralPubMed
18.
Iwase H, Yamamoto Y, Yamamoto-Ibusuki M et al (2013) Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study (translated from Eng). Br J Cancer 109(6):1537–1542 (in Eng)CrossRefPubMedCentralPubMed
19.
Yardley DA, Noguchi S, Pritchard KI et al (2013) Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis (translated from Eng). Adv Ther 30(10):870–884 (in Eng)CrossRefPubMedCentralPubMed
20.
Rocca A, Farolfi A, Bravaccini S et al (2014) Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer (translated from Eng). Expert Opin Pharmacother 15(3):407–420 (in Eng)CrossRefPubMed
21.
Burzykowski T, Buyse M, Piccart-Gebhart MJ et al (2008) Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer (translated from Eng). J Clin Oncol 26(12):1987–1992 (in Eng)CrossRefPubMed
22.
Robertson JF, Howell A, Gorbunova VA et al (2005) Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant (translated from Eng). Breast Cancer Res Treat 92(2):169–174 (in Eng)CrossRefPubMed
Metadaten
Titel
Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor
verfasst von
Hirotaka Iwase
Publikationsdatum
01.04.2015
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 2/2015
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-015-0795-6

Weitere Artikel der Ausgabe 2/2015

International Journal of Clinical Oncology 2/2015 Zur Ausgabe

Original Article

Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS)

Original Article

Analysis of prognostic factors for patients with bulky squamous cell carcinoma of the uterine cervix who underwent neoadjuvant chemotherapy followed by radical hysterectomy

Original Article

Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients

Original Article

Impact of variant histology on disease aggressiveness and outcome after nephroureterectomy in Japanese patients with upper tract urothelial carcinoma

Original Article

Combination of MUC1 and MUC4 expression predicts clinical outcome in patients with oral squamous cell carcinoma

Original Article

Disease control and clinicopathological prognostic factors of total pharyngolaryngectomy for hypopharyngeal cancer: a single-center study

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise